In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $2.45 in the prior trading day, Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $2.4, down -2.04%. In other words, the price has decreased by -$2.04 from its previous closing price. On the day, 11.39 million shares were traded. IOVA stock price reached its highest trading level at $2.48 during the session, while it also had its lowest trading level at $2.351.
Ratios:
Our goal is to gain a better understanding of IOVA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.41. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $2.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 952723136 and an Enterprise Value of 704414144. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.80 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 2.813 whereas that against EBITDA is -1.875.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.76, which has changed by -0.58404076 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $7.03, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is 0.46%, while the 200-Day Moving Average is calculated to be -0.35%.
Shares Statistics:
The stock has traded on average 14.46M shares per day over the past 3-months and 10959200 shares per day over the last 10 days, according to various share statistics. A total of 385.46M shares are outstanding, with a floating share count of 338.65M. Insiders hold about 14.69% of the company’s shares, while institutions hold 47.05% stake in the company. Shares short for IOVA as of 1767139200 were 119070866 with a Short Ratio of 8.23, compared to 1764288000 on 118939462. Therefore, it implies a Short% of Shares Outstanding of 119070866 and a Short% of Float of 32.36.
Earnings Estimates
At present, 9.0 analysts are actively evaluating the performance of Iovance Biotherapeutics Inc (IOVA) in the stock market.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.14 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.99 and -$1.15 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$0.61, with 9.0 analysts recommending between -$0.41 and -$1.03.
Revenue Estimates
11 analysts predict $82.17M in revenue. The current quarter. It ranges from a high estimate of $93.3M to a low estimate of $74.27M. As of. The current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $73.69MFor the next quarter, 11 analysts are estimating revenue of $82.76M. There is a high estimate of $94.2M for the next quarter, whereas the lowest estimate is $74.1M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $270M, while the lowest revenue estimate was $251M, resulting in an average revenue estimate of $259.45M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $421.03M in the next fiscal year. The high estimate is $540.4M and the low estimate is $356.2M.
